FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000223020> ?p ?o ?g. }

• W2000223020 abstract "Prostate cancer is one of the most frequently diagnosed cancer entities in men. It can be estimated that in 80% of all men reaching the age of 80 years prostate tumors are present. Since a depletion of testosterone in prostate cancer therapies is often performed, androgen-dependent and -independent prostate carcinoma cell lines have been widely used to establish mouse in vivo xenograft models in order to identify novel drugs helping to eliminate prostate tumors. A commercially available LNCaP cell line was shown to be androgen-dependent since addition of synthetic androgens to androgen-free culture medium was able to restore proper cell proliferation in cell culture. However, when implanted in SCID mice in order to establish a xenograft model, the take rate turned out to be very low and tumor growth was highly heterogeneously. Therefore, we resected and recultivated one of the few well-growing tumors and reimplanted the arising subpopulation subcutaneously in mice. After performing two rounds of this “subpopulationing” procedure we could generate a new cell line, LNCaP-(Z2), which was able to form tumors in mice with a take rate of nearly 100%, but still shows heterogenous tumor growth similar to other subcutaneously implanted prostate cancer cells (e.g. PC-3). In order to demonstrate an androgen dependency of our new LNCaP subpopulation model in vivo we used castrated mice and implanted them subcutaneously in the absence or presence of also subcutaneously inoculated testosterone pellets. For comparison PC-3 prostate cancer cells were also implanted subcutaeously in the presence or absence of testosterone. Whereas no influence of testosterone was detectable on the growth behavior of subcutaneous PC-3 xenograft tumors, the development of the LNCaP-(Z2) xenografts was strictly dependent on testosterone release. We then implanted fire fly luciferase expressing LNCaP-(Z2)-luc cells orthotopically into the prostate of castrated male SCID beige mice with or without testosterone supplementation to show testosterone-dependency. Finally, treatment of Bicalutamide, a typical member of the class of anti-androgens, which is frequently used in the treatment of prostate cancer, led to significant inhibition of tumor growth using our improved subpopulation LNCaP-(Z2) in vivo model. Bicalutmid and Flutamid, another anti-androgen agent, were used for treatment in the orthopical in vivo model. Both compounds showed a noticeable anti-tumoral effect at necropsy. Thus, we could demonstrate the model9s potency as a testosterone-dependent in vivo tool suitable for screening and development of novel anti-prostate cancer drugs. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B14. Citation Format: Andreas Lingnau, Sandra Moor, Steffen Hoffmann, Cynthia Schaefer-Obodozie, Ulrike Leisegang, Klotzbuecher Andrea, Schaechtele Christoph. Characterization of an in vivo generated subpopulation of human LNCaP prostate cancer cells as an improved testosterone-dependent subcutaneous as well as orthotopic in vivo mouse xenograft model for compound testing. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B14." @default.
• W2000223020 created "2016-06-24" @default.
• W2000223020 creator A5007097346 @default.
• W2000223020 creator A5012384841 @default.
• W2000223020 creator A5013517129 @default.
• W2000223020 creator A5031927845 @default.
• W2000223020 creator A5067837697 @default.
• W2000223020 creator A5080122954 @default.
• W2000223020 creator A5090029295 @default.
• W2000223020 date "2013-11-01" @default.
• W2000223020 modified "2023-09-25" @default.
• W2000223020 title "Abstract B14: Characterization of an in vivo generated subpopulation of human LNCaP prostate cancer cells as an improved testosterone-dependent subcutaneous as well as orthotopic in vivo mouse xenograft model for compound testing." @default.
• W2000223020 doi "https://doi.org/10.1158/1535-7163.targ-13-b14" @default.
• W2000223020 hasPublicationYear "2013" @default.
• W2000223020 type Work @default.
• W2000223020 sameAs 2000223020 @default.
• W2000223020 citedByCount "0" @default.
• W2000223020 crossrefType "proceedings-article" @default.
• W2000223020 hasAuthorship W2000223020A5007097346 @default.
• W2000223020 hasAuthorship W2000223020A5012384841 @default.
• W2000223020 hasAuthorship W2000223020A5013517129 @default.
• W2000223020 hasAuthorship W2000223020A5031927845 @default.
• W2000223020 hasAuthorship W2000223020A5067837697 @default.
• W2000223020 hasAuthorship W2000223020A5080122954 @default.
• W2000223020 hasAuthorship W2000223020A5090029295 @default.
• W2000223020 hasConcept C121608353 @default.
• W2000223020 hasConcept C126322002 @default.
• W2000223020 hasConcept C134018914 @default.
• W2000223020 hasConcept C143998085 @default.
• W2000223020 hasConcept C150903083 @default.
• W2000223020 hasConcept C207001950 @default.
• W2000223020 hasConcept C2776235491 @default.
• W2000223020 hasConcept C2777911890 @default.
• W2000223020 hasConcept C2779279991 @default.
• W2000223020 hasConcept C2779723316 @default.
• W2000223020 hasConcept C2780192828 @default.
• W2000223020 hasConcept C502942594 @default.
• W2000223020 hasConcept C54355233 @default.
• W2000223020 hasConcept C71315377 @default.
• W2000223020 hasConcept C71924100 @default.
• W2000223020 hasConcept C81885089 @default.
• W2000223020 hasConcept C86803240 @default.
• W2000223020 hasConceptScore W2000223020C121608353 @default.
• W2000223020 hasConceptScore W2000223020C126322002 @default.
• W2000223020 hasConceptScore W2000223020C134018914 @default.
• W2000223020 hasConceptScore W2000223020C143998085 @default.
• W2000223020 hasConceptScore W2000223020C150903083 @default.
• W2000223020 hasConceptScore W2000223020C207001950 @default.
• W2000223020 hasConceptScore W2000223020C2776235491 @default.
• W2000223020 hasConceptScore W2000223020C2777911890 @default.
• W2000223020 hasConceptScore W2000223020C2779279991 @default.
• W2000223020 hasConceptScore W2000223020C2779723316 @default.
• W2000223020 hasConceptScore W2000223020C2780192828 @default.
• W2000223020 hasConceptScore W2000223020C502942594 @default.
• W2000223020 hasConceptScore W2000223020C54355233 @default.
• W2000223020 hasConceptScore W2000223020C71315377 @default.
• W2000223020 hasConceptScore W2000223020C71924100 @default.
• W2000223020 hasConceptScore W2000223020C81885089 @default.
• W2000223020 hasConceptScore W2000223020C86803240 @default.
• W2000223020 hasLocation W20002230201 @default.
• W2000223020 hasOpenAccess W2000223020 @default.
• W2000223020 hasPrimaryLocation W20002230201 @default.
• W2000223020 hasRelatedWork W1599721248 @default.
• W2000223020 hasRelatedWork W2027582608 @default.
• W2000223020 hasRelatedWork W2028298161 @default.
• W2000223020 hasRelatedWork W2039416797 @default.
• W2000223020 hasRelatedWork W2051967652 @default.
• W2000223020 hasRelatedWork W2091306629 @default.
• W2000223020 hasRelatedWork W2114421044 @default.
• W2000223020 hasRelatedWork W2166919244 @default.
• W2000223020 hasRelatedWork W2167950790 @default.
• W2000223020 hasRelatedWork W2333231505 @default.
• W2000223020 hasRelatedWork W2341474189 @default.
• W2000223020 hasRelatedWork W2360511562 @default.
• W2000223020 hasRelatedWork W2378813567 @default.
• W2000223020 hasRelatedWork W2388426305 @default.
• W2000223020 hasRelatedWork W2390712058 @default.
• W2000223020 hasRelatedWork W2412393469 @default.
• W2000223020 hasRelatedWork W2955804302 @default.
• W2000223020 hasRelatedWork W3029750894 @default.
• W2000223020 hasRelatedWork W3083452061 @default.
• W2000223020 hasRelatedWork W18331180 @default.
• W2000223020 isParatext "false" @default.
• W2000223020 isRetracted "false" @default.
• W2000223020 magId "2000223020" @default.
• W2000223020 workType "article" @default.